# US 2020/0390773 A1 · Topical acyclovir formulations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390773 A1
- Document ID: US20200390773A1
- Status: Published application
- Kind: A1
- Application number: 16/899,952
- Filed: 2020-06-12
- Published: 2020-12-17
- Earliest claimed: 2019-06-14
- Assignees: Propella Therapeutics, Inc.
- Applicants: Propella Therapeutics, Inc.
- Inventors: Matthew J. Sharp
- Web page: https://patentgrep.com/patent/US20200390773A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation.

## Claims

### Claim 1

An aqueous gel formulation comprising acyclovir dissolved or partially suspended in an aqueous gel,
wherein the acyclovir is in an amount of about 0.05% to about 0.5% by weight of the aqueous gel formulation,
wherein the aqueous gel comprises a solvent system and an effective amount of a gel-forming agent,
wherein the solvent system comprises water in an amount of about 20% to about 80% by weight of the aqueous gel formulation; and one or more water-miscible organic solvents in an amount of about 15% to about 70% by weight of the aqueous gel formulation; and
wherein the aqueous gel formulation is formulated for topical use.

### Claim 2 (depends on 1)

The aqueous gel formulation of claim 1, wherein the one or more water-miscible organic solvents are selected from propylene glycol, glycerol, diethylene glycol monoethyl ether, dimethyl sulfoxide, a low molecular weight polyethylene glycol, and combinations thereof.

### Claim 3 (depends on 1)

The aqueous gel formulation of claim 1, wherein the one or more water-miscible organic solvents comprise diethylene glycol monoethyl ether in an amount of about 10% to about 60% by weight.

### Claim 4 (depends on 1)

The aqueous gel formulation of claim 1, wherein the one or more water-miscible organic solvents comprise a low molecular weight polyethylene glycol in an amount of about 5% to about 40% by weight.

### Claim 5 (depends on 4)

The aqueous gel formulation of claim 4, wherein the low molecular weight polyethylene glycol is polyethylene glycol 400.

### Claim 6

An emulsified gel formulation comprising acyclovir dissolved or partially suspended in an emulsified gel,
wherein the acyclovir is in an amount of about 0.05% to about 0.5% by weight of the emulsified gel formulation,
wherein the emulsified gel comprises a solvent system, an oil, an emulsifier and an effective amount of a gel-forming agent,
wherein the solvent system comprises water in an amount of about 20% to about 80% by weight of the emulsified gel formulation; and one or more water-miscible organic solvents in an amount of about 15% to about 70% by weight of the emulsified gel formulation; and
wherein the emulsified gel formulation is formulated for topical use.

### Claim 7 (depends on 6)

The emulsified gel formulation of claim 6, wherein the one or more water-miscible organic solvents are selected from propylene glycol, glycerol, diethylene glycol monoethyl ether, dimethyl sulfoxide, a low molecular weight polyethylene glycol, and combinations thereof.

### Claim 8 (depends on 6)

The emulsified gel formulation of claim 6, wherein the one or more water-miscible organic solvents comprise diethylene glycol monoethyl ether in an amount of about 10% to about 60% by weight.

### Claim 9 (depends on 6)

The emulsified gel formulation of claim 6, wherein the one or more water-miscible organic solvents comprise a low molecular weight polyethylene glycol in an amount of about 5% to about 40% by weight.

### Claim 10 (depends on 7)

The emulsified gel formulation of claim 7, wherein the low molecular weight polyethylene glycol is polyethylene glycol 400.

### Claim 11 (depends on 6)

The emulsified gel formulation of claim 6, wherein the oil is a triglyceride of caprylic and/or capric acid or a mixed ester of palm oil or coconut oil in an amount of about 1% to about 20% by weight of the emulsified gel formulation.

### Claim 12 (depends on 6)

The emulsified gel formulation of claim 6, wherein the emulsifier comprises an acrylamide and sodium acryloyldimethyl taurate copolymer dispersed in isohexadecane and a non-ionic surfactant.

### Claim 13

A non-aqueous gel formulation comprising acyclovir dissolved or partially suspended in a non-aqueous gel,
wherein the acyclovir is in an amount of about 0.05% to about 0.5% by weight of the non-aqueous gel formulation,
wherein the non-aqueous gel comprises a solvent system and an effective amount of a gel-forming agent,
wherein the solvent system comprises one or more solvents selected from propylene glycol, glycerol, diethylene glycol monoethyl ether, dimethyl sulfoxide, a low molecular weight polyethylene glycol, and combinations thereof; and
wherein the non-aqueous gel formulation is formulated for topical use.

### Claim 14

An aqueous gel formulation comprising: a) acyclovir in an amount of about 0.05% to about 0.5% by weight of the aqueous gel formulation; b) water; c) diethylene glycol monoethyl ether; and d) a gel-forming agent.

### Claim 15 (depends on 14)

The aqueous gel formulation of claim 14, further comprising a low molecular weight polyethylene glycol with an average molecular weight less than 700.

### Claim 16 (depends on 15)

The aqueous gel formulation of claim 15, wherein the low molecular weight polyethylene glycol is PEG 400.

### Claim 17 (depends on 15)

The aqueous gel formulation of claim 15, wherein the weight ratio of diethylene glycol monoethyl ether to the low molecular weight polyethylene glycol ranges from about 20:1 to about 1:5.

### Claim 18 (depends on 15)

The aqueous gel formulation of claim 15, wherein the weight ratio of diethylene glycol monoethyl ether to the low molecular weight polyethylene glycol ranges from about 10:1 to about 2:1.

### Claim 19 (depends on 14)

The aqueous gel formulation of claim 14, wherein the weight ratio of water to diethylene glycol monoethyl ether ranges from about 5:1 to about 1:5.

### Claim 20 (depends on 14)

The aqueous gel formulation of claim 14, comprising by weight of the aqueous gel formulation, water in an amount of about 30-50%, diethylene glycol monoethyl ether in an amount of about 35-65%, and PEG 400 in an amount of about 5-15%.

### Claim 21 (depends on 14)

The aqueous gel formulation of claim 14, wherein the gel-forming agent is a crosslinked polyacrylic acid.

### Claim 22 (depends on 14)

The aqueous gel formulation of claim 14, wherein the pH of the aqueous gel formulation is about 4 to 8.

### Claim 23 (depends on 14)

The aqueous gel formulation of claim 14, wherein acyclovir is the only active ingredient.

### Claim 24 (depends on 14)

The aqueous gel formulation of claim 14, further comprising an antioxidant or preservative selected from butylated hydroxytoluene, phenoxyethanol, sodium metabisulfite, EDTA, ascorbic acid, and combinations thereof.

### Claim 25 (depends on 14)

The aqueous gel formulation of claim 14, which is substantially free of acyclovir in a solid form.

### Claim 26 (depends on 14)

A method of treating or preventing herpes labialis in a subject in need thereof comprising topically applying to the subject an effective amount of the aqueous gel formulation of claim 14.

### Claim 27 (depends on 14)

A method of treating or preventing herpes viral infections of the skin or mucosa of a subject in need thereof comprising topically applying to the subject an effective amount of the aqueous gel formulation of claim 14.

### Claim 28 (depends on 14)

A method of treating or preventing herpes zoster infections of the skin or mucosa of a subject in need thereof comprising topically applying to the subject an effective amount of the aqueous gel formulation of claim 14.

### Claim 29 (depends on 14)

A method of treating or preventing herpes varicella infections of the skin or mucosa of a subject in need thereof comprising topically applying to the subject an effective amount of the aqueous gel formulation of claim 14.

### Claim 30 (depends on 14)

A method of treating or preventing one or more diseases selected from genital herpes simplex, neonatal herpes simplex, cold sores, shingles, acute chickenpox, acute mucocutaneous HSV infections, herpes of the eye, and herpes simplex blepharitis, the method comprising topically applying to a subject in need thereof an effective amount of the aqueous gel formulation of claim 14.
